SCHEMBL5361291

SCHEMBL5361291

O=C1Nc2ccc(I)cc2C1=Cc1c(O)cc(O)cc1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.61
RAF1 P04049 3/20 0.61
MAP1LC3B Q9GZQ8 3/20 0.61
PLK4 O00444 3/20 0.61
PLK1 P53350 2/20 0.61
EGFR P00533 1/20 0.61
NTRK1 P04629 1/20 0.61
ARAF P10398 1/20 0.61
PIM1 P11309 1/20 0.61
BRAF P15056 1/20 0.61
CSNK2A1 P68400 1/20 0.61
PIM3 Q86V86 1/20 0.61
SIRT2 Q8IXJ6 1/20 0.61
SIRT1 Q96EB6 1/20 0.61
MYOC Q99972 1/20 0.61
DYRK4 Q9NR20 1/20 0.61
SIRT3 Q9NTG7 1/20 0.61
SIRT5 Q9NXA8 1/20 0.61
MAP3K20 Q9NYL2 1/20 0.61
PIM2 Q9P1W9 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7134225 0.84 MAPT (0.74) MAPTRAF1MAP1LC3BPLK4PLK1
SCHEMBL5368368 0.84 MAPT (0.58) MAPTRAF1MAP1LC3BPLK4PLK1
SCHEMBL5370064 0.82 PSEN1 (0.71) MAPTRAF1MAP1LC3BPLK4PLK1
SCHEMBL5357740 0.81 MAPT (0.58) MAPTRAF1MAP1LC3BPLK4PLK1
SCHEMBL7140867 0.81 RAF1 (0.76) MAPTRAF1MAP1LC3BPLK4PLK1
SCHEMBL5358330 0.80 MAPT (0.52) MAPTRAF1MAP1LC3BPLK4PLK1
SCHEMBL5359400 0.80 PLK4 (0.70) MAPTRAF1MAP1LC3BPLK4PLK1
SCHEMBL5364818 0.78 MAP3K7 (0.67) MAPTRAF1MAP1LC3BPLK4PLK1
SCHEMBL7130967 0.78 NTRK1 (0.54) MAPTRAF1MAP1LC3BPLK4PLK1
SCHEMBL5363549 0.78 MAPT (0.54) MAPTRAF1MAP1LC3BPLK4PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MAPT 3048/4885RAF1 245/4885MAP1LC3B 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.